# A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Source: https://onco.cc/trials/nct06733441/  
OnCo record `nct06733441` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Zeprumetostat run by Treeline Biosciences, Inc., active and no longer recruiting.

## Summary

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma is a phase 1 interventional study registered as NCT06733441 by Treeline Biosciences, Inc., with 50 participants planned, started 2024-12-16. Conditions recorded: Lymphoma. Interventions recorded: TLN-254 and TLN-254.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06733441
- Phase: 1
- Setting: Phase 1b, Randomized, Dose Optimization Study to Assess the Anti-Tumor Activity, Safety, and Pharmacokinetics of TLN-254 in Patients With Relapsed or Refractory T-cell Lymphoma
- Sponsor: Treeline Biosciences, Inc.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06733441: https://clinicaltrials.gov/study/NCT06733441

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Zeprumetostat](https://onco.cc/drugs/zeprumetostat/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/), [Treeline Biosciences](https://onco.cc/companies/treeline-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06733441.json